Actithera

Executive Summary

Actithera is a private, preclinical-stage biotech based in San Diego, founded in 2018, focused on developing next-generation radioligand therapies (RLTs) for oncology. The company leverages a proprietary chemistry platform to design small molecules and modified peptides that maximize tumor radiation retention while minimizing exposure to healthy tissues, potentially improving the therapeutic index of RLTs. Actithera is preparing its lead asset for IND-enabling studies, positioning itself to enter the competitive radiopharmaceutical landscape. The company's private status and early stage limit public data, but its focus on differentiated chemistry and tumor selectivity suggests a novel approach in the rapidly growing RLT space, which has seen recent approval and commercial success of similar agents. With no disclosed funding history or pipeline details, Actithera represents a high-risk, high-reward opportunity typical of early-stage biotechs. The company's success hinges on advancing its preclinical candidates through IND clearance and initial clinical proof-of-concept, as well as securing sufficient capital to support these activities.

Upcoming Catalysts (preview)

• Q4 2026Lead Asset IND Submission65% success
• Q3 2026Series A or Seed Extension Financing75% success
• 2027Strategic Partnership or Licensing Deal30% success